Effects of Short-term Intensive Statin Therapy on Lipid Levels
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: statin.
- Who it may be relevant to
- Registry conditions: Ischemic Stroke. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effects of Short-term Intensive Statin Therapy on Lipid Levels in Patients With Ischemic Stroke or Large Artery Atherosclerosis: A Prospective Observational Study
Overview
Acute cerebral infarction (ACI), often linked to arterial stenosis, is a major cause of death and disability. Statins are cornerstone therapies for secondary prevention, effectively lowering LDL-C and stabilizing plaques. However, patient response to intensive statin therapy varies significantly. This prospective study aims to analyze the short-term lipid-lowering effects and influencing factors of such therapy in ACI patients with stenosis, to guide personalized treatment and improve outcomes.
Interventions
- Drug statin
Atorvastatin 40-80mg/day, Rosuvastatin 20mg/day
Primary outcome measures
- Absolute reduction in Low-Density Lipoprotein Cholesterol [Time frame: 7±1 days]
Secondary outcome measures (2)
- Absolute and relative reductions in other lipid parameters (Total Cholesterol, Triglyceride, High-Density Lipoprotein Cholesterol, Lipoprotein a) [Time frame: 7±1 days]
- Changes in high-sensitivity C-reactive protein [Time frame: 7±1 days]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years;
- Diagnosis of ischemic stroke (within 14 days of onset) confirmed by cranial CT/MRI; or imaging-confirmed intracranial/extracranial atherosclerotic stenosis (stenosis rate ≥ 50%);
- Intensive statin therapy (e.g., atorvastatin 40-80 mg/day or rosuvastatin 20 mg/day) initiated within 24 hours of admission, with a planned continuous application for at least one week;
- Signed informed consent form.
Exclusion criteria
- Use of statin therapy within 1 week prior to admission;
- Receiving other lipid-lowering treatments;
- Presence of other serious comorbidities (e.g., malignant tumors, end-stage heart failure) with an expected survival of <1 year;
- Pregnant or lactating women;
- Participation in other drug clinical trials within 3 months;
- Other conditions deemed unsuitable by the investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Lu Wang — Shenyang
Identifiers
NCT: NCT07344610 · Y (2025) 527